Home / Market News / $PTGX
benzinga Corporate Catalyst Impact 65/100 ● neutral

UBS Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $184

Oct 12, 2026, 1:47 PM UTC · Primary ticker $PTGX

UBS analyst Alice Nettleton has initiated coverage on Protagonist Therapeutics (PTGX) with a 'Buy' rating and a price target of $184. This analyst coverage and positive rating could generate increased investor interest and potentially drive the stock price upwards.

UBS analyst Alice Nettleton has initiated coverage on Protagonist Therapeutics (PTGX) with a 'Buy' rating and a significant price target of $184. This event is a positive catalyst for PTGX as it signals increased institutional interest and a professional endorsement of the company's prospects. For traders, this could lead to short-term upward price momentum as investors react to the new coverage and target. Long-term implications depend on the company's ability to meet or exceed the analyst's expectations, but the initial 'Buy' rating provides a strong foundation. The key opportunity for traders is to capitalize on the potential immediate price appreciation following this news.

$PTGX positive New 'Buy' rating and high price target from UBS
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.